Use of a flavanoid extract obtained from the species talipariti elatum sw, formulations comprising same and treatment method

Abstract

This invention is related to the field of healthcare and especially to the treatment of memory disorders. The invention consists in the preparation of oral pharmaceutical formulations from an extract of flavonoids obtained from the species Talipairti elatum Sw., which acts improving the different types of memory, both in the short and long-term associated with different pathologies and with population aging in humans.

1 . A flavonoid extract from the petals of  Talipariti elatum  Sw. for use in the treatment of memory disorders. 
     
     
         2 . A pharmaceutical formulation for oral administration comprising a therapeutically effective amount of the extract according to  claim 1 , together with:
 at least one hydrophilic binding agent,   at least one diluent agent and   at least one disintegrating agent.   
     
     
         3 . The pharmaceutical formulation according to  claim 2  characterized by being in solid form. 
     
     
         4 . The pharmaceutical formulation according to  claim 3  characterized as being in the form of granulates. 
     
     
         5 . The pharmaceutical formulation according to  claim 3  characterized as being in tablet form. 
     
     
         6 . The pharmaceutical formulation according to  claim 3  characterized as being in capsule form. 
     
     
         7 . The pharmaceutical formulation according to  claim 2  characterized because the hydrophilic binding agent is present between 2 and 6% in weight with respect to the weight of the flavonoid extract from the petals of  Talipariti elatum  Sw., the diluting agent is present in 16 and 80% in weight with respect to the weight of the flavonoid extract from the petals of  Talipariti elatum  Sw., and the disintegrating agent is present between 1% and 9% in weight with respect to the weight of the flavonoid extract from the petals of  Talipariti elatum  Sw. 
     
     
         8 . The pharmaceutical formulation, according to  claim 2 , characterized by the hydrophilic binding agent being starch or polyvinylpyrrolidone, the diluting agent being microcrystalline cellulose or mixtures thereof with starch, and the disintegrating agent being sodium starch glycolate. 
     
     
         9 . The pharmaceutical formulation, in accordance with  claim 8 , comprises 52 to 72% in weight of flavonoid extract from the petals of  Talipariti elatum  Sw., 4 to 29% in weight of starch, 13 to 18% in weight of microcrystalline cellulose, 4 to 6% in weight of sodium starch glycolate. 
     
     
         10 . The pharmaceutical formulation, in accordance with  claim 8 , comprises 52 to 85% in weight of flavonoid extract from the petals of  Talipariti elatum  Sw., 1 to 2% in weight of polyvinylpyrrolidone, 10 to 46% in weight of microcrystalline cellulose, 1 to 6% in weight of starch sodium glycolate. 
     
     
         11 . The pharmaceutical formulation according to  claim 8  is characterised because the hydrophilic binding agent is starch and is present in at least 5% in weight of the flavonoid extract from the petals of  Talipariti elatum  Sw, the diluting agent is microcrystalline cellulose and is present between 20 and 30% in weight of the flavonoid extract from the petals of  Talipariti elatum  Sw. and the disintegrating agent is sodium starch glycolate and is present in approximately 8% in weight of the active ingredient. 
     
     
         12 . The pharmaceutical formulation according to  claim 8  is characterized because the hydrophilic binder agent is polyvinylpyrrolidone and is present between 2 and 3% in weight with respect to the weight of the flavonoid extract from the petals of  Talipariti elatum  Sw., the diluting agent is microcrystalline cellulose and is present between 12 and 25% in weight with respect to the weight of the flavonoid extract from the petals of  Talipariti elatum  Sw. and the disintegrating agent is sodium starch glycolate and is present between 1 and 3% in weight with respect to the weight of the active ingredient. 
     
     
         13 . The pharmaceutical formulation according to  claim 2 , characterized because it presents in its composition, additionally, a lubricating compound, preferably magnesium stearate. 
     
     
         14 . The pharmaceutical formulation according to  claim 2  characterized as being in liquid form. 
     
     
         15 . The pharmaceutical formulation for oral administration, according to  claim 14 , comprising a therapeutically effective amount of flavonoid extract from the petals of pharmaceutically acceptable  Talipariti elatum  Sw. characterized by the fact that it also contains: at least one preservative, at least one aromatizer, at least one Sweetener, at least one acidulant, at least one moisturizer and at least one liquid vehicle. 
     
     
         16 . The pharmaceutical formulation in accordance with  claim 15  containing: 0.5% to 1.5% w/v flavonoid extract from the petals of  Talipariti elatum  Sw. 0.1% to 0.5% w/v of preservatives 0.01% to 0.2% w/v of aromatizers 0.05% to 0.5% w/v of Sweeteners 0.15% to 0.5% w/v of acidulants 5% to 15% w/v of moisturizers 30% to 80% w/v of hydrogenated glucose syrup purified water, a sufficient amount up to 100%. 
     
     
         17 . The pharmaceutical formulation according to  claim 15 , characterized because the aromatizing agent is the strawberry aroma. 
     
     
         18 . The pharmaceutical formulation according to any of  claim 15 , in which sodium benzoate is preferably used as a preservative agent. 
     
     
         19 . The pharmaceutical formulation according to  claim 15  where citric acid is used as an acidulant. 
     
     
         20 . The pharmaceutical formulation according to  claim 17  containing 1% (0.01 g/ml) flavonoid extract from the petals of  Talipariti elatum  Sw., 0.2% (0.002 g/ml) sodium benzoate, 0.025% (0.00025 g/ml) strawberry aroma, 0.35% (0.0035 g/ml) citric acid, 64% (0.64 g/ml) hydrogenated glucose syrup, purified water, in sufficient quantity up to 1 ml, and optionally one or more Sweetening or moisturising agents. 
     
     
         21 . The formulation in accordance with  claim 20  contains as Sweetener 0.2% (0.002 g/ml) of sodium saccharin and as moisturizer 10% (0.1 g/ml) of glycerol. 
     
     
         22 . Pharmaceutical formulations in accordance with  claim 2  for use in the treatment of short-term and long-term memory disorders. 
     
     
         23 . A method for the treatment of short- and long-term memory disorders where the method involves the step of administering to a subject with such disorders a therapeutically effective amount of the extract in accordance with  claim 1  or any pharmaceutical formulation in accordance with  claim 2 .